Can Cancer Be Mistaken for Fatty Liver?

Can cancer be mistaken for fatty liver? The short answer is yes, and while it is uncommon, it is a recognised clinical challenge that specialists take seriously. Certain liver cancers and metastatic deposits can produce imaging appearances that overlap with hepatic steatosis, particularly on standard ultrasound. Understanding which cancers are most likely to mimic fatty liver, how doctors distinguish between the two, and which symptoms should prompt further investigation can help patients ask the right questions and ensure that any concerning findings receive the attention they deserve.

Can cancer really be mistaken for fatty liver on a scan?

Yes, certain cancers can produce imaging appearances that overlap with fatty liver disease, particularly on ultrasound without contrast. Contrast-enhanced MRI or multiphase CT is usually needed to reach a confident diagnosis.

Yes, certain cancers can appear similar to fatty liver disease on imaging, and misidentification, while uncommon, is a recognised clinical challenge. Fatty liver disease, or hepatic steatosis, causes the liver to appear brighter than usual on ultrasound and shows characteristic signal changes on MRI.^[7][8] Some malignant lesions, particularly those containing fat or causing focal fatty infiltration, can produce overlapping appearances that make initial interpretation difficult.

Ultrasound is often the initial imaging test for liver abnormalities, but it may not definitively characterise focal liver lesions, particularly against a background of diffuse fatty change. Contrast-enhanced MRI or multiphase CT is frequently needed to reach a confident diagnosis. The risk of misinterpretation can be greater when imaging is performed without contrast or when the radiologist does not have access to a full clinical history.

Modern imaging protocols, including contrast-enhanced MRI and CT with dedicated liver phases, have substantially improved the ability to distinguish benign fatty change from malignant lesions. When a scan result is uncertain or when clinical features do not fit the imaging findings, further investigation is always warranted. Patients should feel empowered to ask their clinician what the next step is if they have concerns about an inconclusive result.

Which cancers are most likely to mimic fatty liver disease?

Hepatocellular carcinoma, metastatic liver disease, and fat-containing tumours such as hepatic angiomyolipoma are most likely to be confused with fatty liver on imaging. Focal fatty infiltration can also mimic a tumour, and vice versa.

Hepatocellular carcinoma (HCC), metastatic liver disease, and certain fat-containing tumours are among the lesions most likely to be confused with fatty liver on imaging. HCC, the most common primary liver cancer, frequently arises in livers already affected by chronic disease, including non-alcoholic fatty liver disease (NAFLD), making it harder to detect against an already abnormal background.^[2][3] Some HCC tumours contain fat, which can further blur the distinction on standard ultrasound.^[6][7]

Metastatic deposits, particularly from colorectal, breast, or pancreatic primaries, can occasionally produce diffuse changes in liver echogenicity that superficially resemble steatosis.^[5] Focal fatty infiltration, a benign condition where fat accumulates unevenly within the liver, can itself mimic a tumour, and the reverse is also true: a focal malignant lesion can be overlooked within an area of fatty change. Indeterminate or suspicious findings of this kind are typically reviewed at a hepatobiliary multidisciplinary team (MDT) meeting.

Rarer tumours such as hepatic lipoma, angiomyolipoma, and well-differentiated liposarcoma contain macroscopic fat and may appear deceptively benign on initial imaging; these are uncommon but recognised diagnostic pitfalls.^[6][7] Cholangiocarcinoma, a cancer of the bile ducts, can also present with subtle liver changes that are not immediately distinguishable from inflammatory or fatty conditions without specialist review. Contrast-enhanced MRI or multiphase CT is usually the next step when any of these possibilities arise. Understanding that these overlaps exist is not a reason for alarm, but it does underline why any persistent or unexplained liver abnormality should be followed up with appropriate specialist imaging and, where indicated, biopsy.

How do doctors tell the difference between fatty liver and cancer?

Doctors use clinical history, blood tests including AFP, and contrast-enhanced MRI or multiphase CT to distinguish fatty liver from cancer. A liver biopsy, decided by an MDT, is used when imaging remains inconclusive.

Doctors use a combination of clinical assessment, blood tests, and advanced imaging to distinguish fatty liver disease from liver cancer, and in some cases a biopsy is required for a definitive answer. The diagnostic process typically begins with a full history, including risk factors for liver disease such as alcohol use, obesity, type 2 diabetes, and viral hepatitis, alongside risk factors for malignancy such as cirrhosis, a known primary cancer elsewhere, or a family history of liver cancer.

Blood tests play an important supporting role. Liver function tests, a full blood count, and inflammatory markers can indicate the pattern of liver injury. Alpha-fetoprotein (AFP) is a tumour marker that may be elevated in HCC, though it is neither sensitive nor specific enough to be used alone.^[4][2] In line with NICE guidance (NG50), six-monthly ultrasound surveillance, with or without AFP, is recommended for eligible people with cirrhosis who would be candidates for HCC treatment; AFP measurement alone is not sufficient and is not mandated.^[2][3]

Contrast-enhanced MRI is currently considered the most accurate non-invasive imaging modality for characterising liver lesions.^[11][12] It can identify the arterial enhancement and washout pattern that is characteristic of HCC, and can distinguish fat-containing lesions from true steatosis using chemical shift sequences.^[7][8] CT with dedicated hepatic arterial and portal venous phases is also widely used. Where imaging remains inconclusive, a liver biopsy, guided by ultrasound or CT, provides tissue for histological analysis. The decision to biopsy is made by a multidisciplinary team (MDT), weighing the diagnostic benefit against procedural risk.

What symptoms should prompt you to ask for further tests?

Unexplained weight loss, jaundice, persistent right upper abdominal pain, dark urine, or a new abdominal lump should never be attributed to fatty liver without further evaluation. New or changing symptoms in someone with a known liver diagnosis always require reassessment.

Several symptoms should prompt a conversation with your GP about whether further investigation of your liver is needed, particularly if you have already been told you have fatty liver disease. Unexplained and unintentional weight loss is one of the most important red flag symptoms and should always be taken seriously. Persistent fatigue that is disproportionate to your activity level, or that has worsened over weeks rather than days, also warrants assessment.

Other symptoms that should not be attributed to fatty liver without further evaluation include:

• Persistent right upper abdominal pain or a sensation of fullness or pressure under the right ribcage

• Jaundice (yellowing of the skin or whites of the eyes)

• Dark urine or pale stools, which can indicate bile duct obstruction

• A new lump or swelling in the abdomen

• Persistent loss of appetite

• Generalised itch, easy bruising or bleeding, or progressive abdominal swelling

• Night sweats or unexplained fevers

• Confusion or unusual drowsiness

Fatty liver disease in its early stages is typically silent, meaning it causes no symptoms at all. If you have been given a diagnosis of fatty liver and then develop any of the above, it is important not to assume the symptoms are simply part of the same condition. New or changing symptoms in someone with a known liver diagnosis should always be reassessed rather than attributed to the existing condition without review. Your GP can arrange repeat blood tests and imaging, and can refer you to a hepatologist or gastroenterologist if there is clinical concern.

When should you seek urgent advice from your GP or specialist?

Contact your GP promptly if you develop jaundice, significant unintentional weight loss, or a new abdominal mass, as these require timely investigation. Jaundice with fever or severe pain warrants same-day urgent assessment.

You should contact your GP promptly, rather than waiting for a routine appointment, if you develop jaundice, significant unintentional weight loss, or a new abdominal mass, as these findings require timely investigation. Jaundice in particular can indicate bile duct obstruction, which may have several causes including cancer, and should not be left to resolve on its own.

If jaundice is accompanied by fever, rigors, or severe abdominal pain, this may indicate a serious condition such as cholangitis and warrants same-day urgent assessment. If you feel acutely unwell, call 999 or attend your nearest emergency department rather than waiting for a GP appointment. NHS 111 can also advise on the right course of action if you are unsure.

Patients who are already under surveillance for cirrhosis or chronic liver disease and who notice a change in their symptoms between scheduled appointments should contact their hepatology team directly rather than waiting. Most liver units have a specialist nurse or advice line for this purpose. If you have a known primary cancer elsewhere and develop new liver-related symptoms, contact your oncology team, as this may indicate the need for restaging imaging.

For most people with a diagnosis of simple fatty liver disease and no concerning symptoms, the appropriate step is to attend scheduled follow-up appointments and to raise any new concerns with their GP. NICE guidance (NG49) on non-alcoholic fatty liver disease recommends regular monitoring in primary care, with referral to secondary care for those with evidence of advanced fibrosis or uncertainty about the diagnosis.^[13] Suspected side effects from any medication used in the management of liver-related conditions can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[14]mhra.gov.uk.

Frequently Asked Questions